Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Selexis to Participate at Several Upcoming Industry Conferences

Selexis SA
Posted on: 05 Sep 17

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today its planned participation at upcoming industry conferences, as follows:

BioProcess International Conference
25 – 28 September 2017, Hynes Convention Center, Boston, USA
Selexis will attend the conference and exhibit along with KBI Biopharma.
For more information, please visit: https://lifesciences.knect365.com/bioprocessinternational/

23 rd  Annual Partnering Conference BIO Europe
6 – 8 November 2017, CityCube Berlin, Berlin, Germany
Selexis will sponsor the conference and participate in the partnering program.
For more information, please visit: https://ebdgroup.knect365.com/bioeurope/

9 th  Annual PEGS Europe Protein & Engineering Summit
13 – 17 November 2017, EPIC SANA Lisboa Hotel, Lisbon, Portugal
Selexis Chief Scientific Officer Pierre-Alain Girod, PhD will present “Genome-Wide Signals Detection for Enhanced Cell Line Productivity and Stability” on Thursday, 16 November at 10:05 a.m. WET as part of the Expression track. Additionally, Selexis is a conference sponsor and exhibitor.
For more information, please visit: http://www.pegsummiteurope.com/

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 80+ drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.

 

FOR MORE INFORMATION

- Web

www.selexis.com

- LinkedIn

www.linkedin.com/company/selexis-sa

- Twitter

www.twitter.com/SelexisSA

- Facebook

www.facebook.com/SelexisSA

 

View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005208/en/

Business Wire
www.businesswire.com

Last updated on: 05/09/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.